Garda raises Assertio acquisition offer to $21.80 per share

Assertio amended its merger agreement with Garda Therapeutics to raise the all-cash tender offer to $21.80 per share, valuing the deal at $153.2 million and removing the contingent value right. The revised bid is a 63.1% premium to Assertio’s March 20 stock price and implies an ~18% spread to the current $18.47 share price, with closing expected in Q2 2026 subject to tender and other conditions. The company also withdrew 2026 guidance and will not hold its Q1 call as it moves toward delisting upon completion.

Analysis

This is now a cleaner deal-arb setup, but the real signal is not the extra premium — it is the narrowing of financing and process risk. A fully financed all-cash bid at a materially higher price typically compresses dispersion in the spread, but the removal of the contingent value right also makes the economics more binary: investors are now underwriting only deal completion, not an optional upside stub. That shifts the trade from “event plus upside” to “pure close-or-bust,” which should tighten borrow, reduce volatility, and pull in arb capital.

Second-order, the competitive takeaway is that Garda likely paid up to avoid a prolonged auction and to neutralize any residual strategic buyer interest after asset divestitures simplified the company. That means the bidder has implicitly marked the asset as more valuable than the market did, but it also suggests the easier re-rating may already be behind us. If the market is pricing an ~18% spread, the implied annualized return is still attractive only if closing remains on schedule; any slippage into Q3 materially erodes the arb case.

The main risk is not price, but execution friction: majority tender thresholds, regulatory surprises, or a last-minute superior bid disruption. Because the company has already monetized non-core assets and withdrawn guidance, there is limited fundamental downside support if the transaction breaks — equity would likely re-rate toward a stripped-down, slower-growth residual value rather than the current headline level. In that break scenario, the market would likely punish holders for owning a now-de-risked but still operationally thin asset base.

Consensus may be underestimating how much of the spread is just compensation for time, not risk. If closing is truly within the next several weeks, the trade is still reasonable; if the process drifts, the spread is expensive versus similar small-cap cash deals. The opportunity is less about directional upside and more about harvesting a tightly bounded event premium with disciplined timing.

Key Decisions for Investors

• Long ASRT vs. cash: buy only on weakness below current levels and size as a short-duration merger-arb position; target is the remaining spread into closing, with a hard stop if closing slips beyond the expected Q2 window.
• Avoid naked long exposure beyond deal-close mechanics; this is now a binary event trade, so monetize gains into any further spread compression rather than underwriting residual upside.
• If borrow is available and the spread tightens materially, consider a small short ASRT against the deal price as a hedged arb leg only after confirming no competing bid risk remains; risk/reward worsens quickly if a topping bid appears.
• For risk-managed accounts, express the view through short-dated call spreads only if the market underprices near-term closure; otherwise prefer stock ownership because option theta will likely overwhelm incremental spread capture.